Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

[1]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[2]  Jun Zhu,et al.  Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. , 2005, JAMA.

[3]  R. Shannon,et al.  Glucagon-Like Peptide-1 Limits Myocardial Stunning following Brief Coronary Occlusion and Reperfusion in Conscious Canines , 2005, Journal of Pharmacology and Experimental Therapeutics.

[4]  M. Mocanu,et al.  Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. , 2005, Diabetes.

[5]  J. Holst,et al.  Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. , 2004, American journal of physiology. Endocrinology and metabolism.

[6]  R. Shannon,et al.  Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy , 2004, Circulation.

[7]  G. Reaven,et al.  Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. , 2004, Journal of the American College of Cardiology.

[8]  R. Shannon,et al.  Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion , 2004, Circulation.

[9]  R. Shannon,et al.  The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. , 2004, Cardiovascular research.

[10]  N. Greig,et al.  Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. , 2003, Diabetes care.

[11]  Felix Zijlstra,et al.  Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. , 2003, Journal of the American College of Cardiology.

[12]  R. Levine,et al.  Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. , 2003, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[13]  L. Rydén,et al.  Glucagon-like peptide-1 (7–36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium , 2003, Peptides.

[14]  H. Taegtmeyer.  Switching Metabolic Genes to Build a Better Heart , 2002, Circulation.

[15]  J. Egan,et al.  Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. , 2002, The Journal of clinical endocrinology and metabolism.

[16]  H. Taegtmeyer,et al.  Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. , 2002, Circulation.

[17]  S. Sollott,et al.  Glucagon-Like Peptide-1 Increases cAMP but Fails to Augment Contraction in Adult Rat Cardiac Myocytes , 2001, Circulation research.

[18]  S. Yusuf,et al.  Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. , 2000, European heart journal.

[19]  S. Anker,et al.  Insulin resistance in chronic heart failure. , 2000, Journal of cardiovascular pharmacology.

[20]  J. Habener,et al.  The glucagon-like peptides. , 1999, Endocrine reviews.

[21]  J. Holst,et al.  Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. , 1999, Diabetes care.

[22]  G. Paolisso,et al.  Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease. , 1999, The American journal of cardiology.

[23]  L. Piegas,et al.  Metabolic Modulation of Acute Myocardial Infarction The ECLA Glucose-Insulin-Potassium Pilot Trial , 1998 .

[24]  C. Apstein.  Glucose-insulin-potassium for acute myocardial infarction: remarkable results from a new prospective, randomized trial. , 1998, Circulation.

[25]  R. Diaz,et al.  Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. , 1998, Circulation.

[26]  S. Anker,et al.  Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. , 1997, Journal of the American College of Cardiology.

[27]  S. Bloom,et al.  Cardiovascular and pancreatic endocrine responses to glucagon‐like peptide‐1(7–36) amide in the conscious calf , 1997, Experimental physiology.

[28]  G. Paolisso,et al.  Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. , 1997, Diabetes & metabolism.

[29]  I. Godsland,et al.  Insulin resistance in chronic heart failure. , 1994, European heart journal.

[30]  K. Minaker,et al.  The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects , 1994, Regulatory Peptides.

[31]  E. Blázquez,et al.  Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. , 1994, The American journal of physiology.

[32]  G. Paolisso,et al.  Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. , 1991, Metabolism: clinical and experimental.